Frequency, predictors and outcome of stent fracture after sirolimus-eluting stent implantation.
BACKGROUND
Recently, stent fracture (SF) of sirolimus-eluting stents (SES) has been shown to be associated with an increased risk of in-stent restenosis. We sought to evaluate the incidence, predictors and clinical outcome of SF after SES implantation in comparable unselected lesions.


METHODS
A total of 430 lesions of 382 patients treated with SES were analyzed. SF was defined as single or multiple stent strut fracture as well as complete separation of stent segments.


RESULTS
At follow-up, SF was identified in 33 of 430 lesions (7.7%). In lesions with SF, the in-stent restenosis was observed more frequently than non-SF lesions (15.2% vs. 4.0%, P=0.004). At 450 days, however, the cumulative rate of major cardiac events was not significantly different between lesions with and without SF (9.1% vs. 7.1%, P=0.722). The risk of SF was independently associated with total stent length (OR 2.22; 95% CI, 1.25 to 3.95; P=0.007), the change in the angulation of the lesion after stenting (OR 1.55; 95% CI, 1.07 to 2.25; P=0.020), and the right coronary artery lesions (OR 3.26; 95% CI, 1.18 to 8.96; P=0.022).


CONCLUSIONS
The occurrence of SF after SES implantation, was found to be relatively common in the particular population, however, did not lead to an increased risk of adverse cardiac events at 450 days, despite a higher incidence of in-stent restenosis.
Umeda
Hisashi
H
Toyota Memorial Hospital, Japan. humedamd@ybb.ne.jp
Gochi
Tomoko
T
Iwase
Mitsunori
M
Izawa
Hideo
H
Shimizu
Takeshi
T
Ishiki
Ryoji
R
Inagaki
Haruo
H
Toyama
Junji
J
Yokota
Mitsuhiro
M
Murohara
Toyoaki
T
D023903:Coronary Restenosis / Q000453:epidemiology* / Q000209:etiology / Q000473:pathology; D054855:Drug-Eluting Stents / Q000009:adverse effects*; D005260:Female; D005500:Follow-Up Studies; D005544:Forecasting; D006801:Humans; D008297:Male; D011446:Prospective Studies; D011475:Prosthesis Failure; D019919:Prosthesis Implantation / Q000009:adverse effects* / Q000295:instrumentation / Q000639:trends*; D020123:Sirolimus / Q000008:administration & dosage*; D013997:Time Factors; D016896:Treatment Outcome
D020123:Sirolimus